JNJ$194.39
$194.79
Chart
Performance
Key Stats
AI JNJ Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
Strong BuyJohnson & Johnson exhibits strong fundamental performance driven by its diversified healthcare business and consistent dividend payouts. While technical indicators suggest some short-term overbought conditions, the long-term outlook remains positive, supported by its stable industry and robust balance sheet. Thematic tailwinds in healthcare innovation and an aging global population provide a favorable backdrop.
Thematic
JNJ benefits from secular growth trends in healthcare, including an aging population, advancements in medical technology, and demand for pharmaceuticals. Its diversified segments (Innovative Medicine and MedTech) provide resilience.
Fundamental
JNJ demonstrates strong financial health, characterized by robust profitability, a solid balance sheet, and consistent free cash flow generation. Its valuation, particularly the P/E ratio, is reasonable given its industry and stability.
Technical
The stock is trading near its 52-week high, indicating a strong upward trend. However, some indicators suggest it might be entering overbought territory, hinting at potential for short-term consolidation.
| Factor | Score |
|---|---|
| Healthcare Demand | 85 |
| Innovation in Medicine | 80 |
| MedTech Advancements | 70 |
| Diversification | 75 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 75 |
| Growth | 70 |
| Balance Sheet Health | 80 |
| Cash Flow | 90 |
| Dividend Performance | 95 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 60 |
| Moving Averages | 85 |
| Volume | 70 |
| Support/Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
The company has consistently beaten EPS estimates for the past several quarters, with an average surprise of 5.1% over the last four reported quarters, indicating strong operational execution and forecasting.
Strong Cash Position
The company reported a strong end cash position of $24.105 billion in Q4 2024, with free cash flow of $18.059 billion in the same period, suggesting robust liquidity and financial flexibility.
Bearish Points (7)
Increasing Quarterly P/E Ratio
The quarterly P/E ratios are showing an increasing trend, with Q1 2025 at 36.0, suggesting that the stock is becoming more expensive on a forward-looking basis.
Slowing Revenue Growth in Certain Quarters
While annual revenue shows growth, some quarterly revenue figures (e.g., Q1 2024: 21.383B vs Q1 2025: 21.893B) indicate a potential slowdown in top-line expansion.
Calendar
August 2025
26
Ex-Dividend Date
September 2025
9
Next Dividend Date
October 2025
14
Next Earnings Date
H: $2.90
A: $2.75
L: $2.63
H: 23.83B
A: 23.73B
L: 23.52B
Profile
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Seasonals
Price Target
175.31 USD
The 39 analysts offering 1 year price forecasts for JNJ have a max estimate of 190.00 and a min estimate of 155.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Spun off from Johnson & Johnson, Kenvue holds J&J's former consumer health brands (e.g., Tylenol, Band-Aid, Neutrogena), making it directly related by corporate lineage and ongoing business operations.
Weight: 95
A major global pharmaceutical company and a direct competitor to J&J's pharmaceutical segment across various therapeutic areas, including oncology, immunology, and vaccines.
Weight: 92
One of the largest medical technology companies, directly competes with J&J's MedTech segment in areas such as surgical technologies, cardiovascular, and neuroscience devices.
Weight: 90
A leading pharmaceutical company with a significant presence in oncology (Keytruda), vaccines, and hospital acute care, directly competing with J&J's pharmaceutical portfolio.